FDA elaborates on Visicol seizures
FDA publishes "1Science Backgrounder" on Visicol-induced seizures on agency website following meeting with InKine execs. Company expressed concern that an FDA letter published in the June 27 New England Journal of Medicine "misstated or omitted" several facts about four seizures reported with use of Visicol, which is indicated for bowel cleansing before colonoscopy. In the website backgrounder, FDA clarifies per InKine's request that more than 210,000 patients have received Visicol (sodium phosphate) and no seizures had been reported since August 2001, although agency notes "there is generally under-reporting of adverse events." Backgrounder also notes that OTC sodium phosphate-containing products have been associated with three seizure reports in the published literature, although they have not been reported to FDA. InKine published a response to the NEJM letter in the online version of the June 27 publication; the response will also appear in the printed July 25 issue...
You may also be interested in...
Splitting Colfax into separate fabrication technology and specialty medical technology businesses will help both sides of the business grow, CEO Matthew Trerotola said recently.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.
Use of per- and polyfluoroalkyl substances in cosmetic products appears to be declining, based on voluntary industry registrations with the US Food and Drug Administration. In any event, NGOs are gunning for PFAS' elimination, and the FDA says available data have yet to give a complete safety picture for PFAS used intentionally in cosmetics or present as impurities.